McGivern JG, McDonough SI: Voltage-gated calcium channels as targets for the treatment of chronic pain. Curr Drug Targets CNS Neurol Disord. 2004; 3(6): 457-478.
2.
Xiao WH, Bennett GJ: Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats. J Pharmacol Exp Ther. 1995; 274(2): 666-672.
3.
Smith MT, Cabot PJ, Ross FB, et al.: The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices. Pain. 2002; 6(1-2): 119-127.
4.
Buchan AM, Gertler SZ, Li H, et al.: A selective N-type Ca(2+)-channel blocker prevents CA1 injury 24 h following severe forebrain ischemia and reduces infarction following focal ischemia. J Cereb Blood Flow Metab. 1994; 14(6): 903-910.
5.
Wermeling D, Drass M, Ellis D, et al.: Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J Clin Pharmacol. 2003; 43(6): 624-636.
6.
Atanassoff PG, Hartmannsgruber MW, Thrasher J, et al.: Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg Anesth Pain Med. 2000; 25(3): 274-278.
7.
PRIALT® package insert. Elan Pharmaceuticals.
8.
Staats PS, Yearwood T, Charapata SG, et al.: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA. 2004; 291(1): 63-70.
